KalVista Pharmaceuticals/$KALV
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Ticker
$KALV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
150
ISIN
US4834971032
Website
KALV Metrics
BasicAdvanced
$644M
-
-$3.72
0.76
-
Price and volume
Market cap
$644M
Beta
0.76
52-week high
$15.50
52-week low
$7.30
Average daily volume
557K
Financial strength
Current ratio
10.438
Quick ratio
9.885
Long term debt to equity
2.989
Total debt to equity
3.984
Interest coverage (TTM)
-63.84%
Management effectiveness
Return on assets (TTM)
-58.15%
Return on equity (TTM)
-150.50%
Valuation
Price to book
4.42
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
-4.777
Growth
Earnings per share change (TTM)
18.42%
3-year earnings per share growth (CAGR)
6.87%
What the Analysts think about KALV
Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.
KALV Financial Performance
Revenues and expenses
KALV Earnings Performance
Company profitability
KALV News
AllArticlesVideos
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
Reuters·3 days ago
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
Business Wire·3 days ago
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $644M as of June 16, 2025.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of June 16, 2025.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of June 16, 2025.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.